Needham Remains a Hold on Amphastar Pharmaceuticals (AMPH)

By Ryan Adsit

Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPHResearch Report) today. The company’s shares closed last Monday at $20.00.

According to, Belanger is a 4-star analyst with an average return of 8.0% and a 48.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.

Amphastar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $20.50.

See today’s analyst top recommended stocks >>

Based on Amphastar Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $1.31 million. In comparison, last year the company had a net profit of $1.87 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments.